CUE (Cue Biopharma) Cyclically Adjusted FCF per Share: $-34.20 (As of Mar. 2026)


CUE Cue Biopharma Inc CUE
63 GF Score
Price $31.86
GF Value $62.49
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cue Biopharma Cyclically Adjusted FCF per Share?

Cue Biopharma CUE -2.45% 63 Cyclically Adjusted FCF per Share is $-34.20 as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 63/100 and a GF Value™ of $62.49 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cue Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-2.301. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-34.20 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-07), Cue Biopharma's current stock price is $31.86. Cue Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-34.20. Cue Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Cue Biopharma  (NAS:CUE) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cue Biopharma Cyclically Adjusted FCF per Share Related Terms


Cue Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Cyclically Adjusted FCF per Share Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -34.20

CUE vs ALPS, AARD, KLRS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Cue Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Cyclically Adjusted Price-to-FCF falls into.


CUE
63GF Score
Cue Biopharma Inc CUE
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cue Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.301/330.2130*330.2130
=-2.301

Current CPI (Mar. 2026) = 330.2130.

Cue Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 236.525 0.000
201609 -2.641 241.428 -3.612
201612 -3.057 241.432 -4.181
201703 -5.843 243.801 -7.914
201706 -5.201 244.955 -7.011
201709 -5.645 246.819 -7.552
201712 -2.709 246.524 -3.629
201803 -15.593 249.554 -20.633
201806 -10.754 251.989 -14.092
201809 -9.835 252.439 -12.865
201812 -5.970 251.233 -7.847
201903 -12.292 254.202 -15.968
201906 -9.620 256.143 -12.402
201909 -12.333 256.759 -15.861
201912 -8.010 256.974 -10.293
202003 -12.352 258.115 -15.802
202006 -7.294 257.797 -9.343
202009 -7.780 260.280 -9.870
202012 -6.930 260.474 -8.785
202103 -12.271 264.877 -15.298
202106 -9.627 271.696 -11.700
202109 -6.360 274.310 -7.656
202112 -9.995 278.802 -11.838
202203 -10.662 287.504 -12.246
202206 -10.953 296.311 -12.206
202209 -5.894 296.808 -6.557
202212 -8.051 296.797 -8.957
202303 -7.280 301.836 -7.964
202306 -6.946 305.109 -7.518
202309 -5.048 307.789 -5.416
202312 -6.966 306.746 -7.499
202403 -5.967 312.332 -6.309
202406 -5.981 314.175 -6.286
202409 -4.406 315.301 -4.614
202412 -3.640 315.605 -3.808
202503 -3.362 319.799 -3.471
202506 -1.082 322.561 -1.108
202509 -2.684 324.800 -2.729
202512 -0.299 324.054 -0.305
202603 -2.301 330.213 -2.301

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-34.20 mean?
Cue Biopharma (CUE) has a Cyclically Adjusted FCF per Share of $-34.20 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's Cyclically Adjusted FCF per Share too high?
Cue Biopharma's current Cyclically Adjusted FCF per Share is $-34.20. Overall, Cue Biopharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Cyclically Adjusted FCF per Share compare to ALPS and AARD?
Cue Biopharma's Cyclically Adjusted FCF per Share of $-34.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Cyclically Adjusted FCF per Share is $-34.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.49, compared to a current price of $31.86 — trading 49% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-34.20. Cue Biopharma's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Cyclically Adjusted FCF per Share is $-34.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $31.86 is trading 49% below its estimated GF Value™ of $62.49. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Cyclically Adjusted FCF per Share: $-34.20
  • GF Value™: $62.49 vs. price of $31.86 (49% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
63GF Score

Get the complete analysis for CUE

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.86
Price
$62.49
GF Value